Company Overview and News
Improving economy reflected by rising interest rates, a growing gross domestic product (GDP), favorable employment backdrop as well as the tax cut should keep the momentum alive for life insurers. Increasing interest rate has come as a boon to insurers with the Fed indicating two more hikes this year, lending an impression of aggressive rate increases. Despite life insurance companies having lowered exposure to interest-sensitive product lines, redesigning and re-pricing products, investment income still forms a major component of the top line.
TMK PRI ATH RGA TMK
That Primerica, Inc. (PRI - Free Report) stock is favored by investors is further corroborated by its share price movement. Shares of the company have rallied 17.5% year to date against its industry's decrease of 12.4%. However, the stock’s growth lagged the Zacks S&P 500 Composite’s gain of 19.9%. With a market capitalization of $5.1 billion, average volume of shares traded in the past three months was 0.
TMK PRI ATH TMK FG
Chicago, IL – August 24, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Athene Holding Ltd. (ATH - Free Report) , Torchmark Corporation (TMK - Free Report) , Genworth Financial, Inc. (GNW - Free Report) , American Equity Investment Life Holding Company (AEL - Free Report) and FGL Holdings (FG - Free Report) .
TMK DECK ATH SF SFN WCG TMK BIG ON NWL CBG HII GNW SFB FG CBRE
Banking on a favorable operating backdrop, the insurance industry seems well-poised for growth. Improving rate environment and a favorable employment backdrop should keep the momentum alive in the life insurance space. The Federal Reserve has already made two rate hikes this year, taking the tally to seven increases since December 2015. The Central Bank has also hinted at four rate raises in 2018. Though the strengthening of U.
TMK ATH GNW TMK FG
2018-08-15 seekingalpha - 7
Berkshire Hathaway increased US Bancorp, Goldman Sachs, Southwest Airlines, and Delta Airlines while reducing Phillips 66.
LBTY PSX THI UAL QSR.WI SIRI MLUSG LBTYK LILAB VRSK BAC BKW UPS USGPF MDLZ SYF TMK BRK.A JNJ BK LILAK VZ BATRA LSXMB WFCNP TMK BATRK LSXMA BATRR VZA STOR BAC CHTR AAPL MON BATRB GM USG QSR DAL WFC FWONB COST LBTYB MA VRSN LBTYA AXTA SNY FWONA V SRG KHC FWONK LSXMK LILA
Estimates for Torchmark Corporation (TMK - Free Report) have been revised upward over the past 30 days, reflecting analysts’ confidence in the stock. The stock has seen the Zacks Consensus Estimate for 2018 bottom line being raised 0.7% to $6.07 and for 2019 earnings move 0.5% north to $6.53. This provider of annuities, whole and term life insurance, accidental death insurance, health insurance, Medicare supplements and long-term healthcare policies carries a favorable Value Score of A.
FOX TMK PRI LMHA GNW TMK LMHB FOXA LM
Sun Life Financial Inc. (SLF - Free Report) reported second-quarter 2018 underlying net income of $565 million (C$729 million), up 10.3% year over year. This improvement was fueled by business growth and a favorable morbidity experience, partially offset by an investment experience, expenses and the impact of the Canadian dollar’s movement.
TMK GD SLF ZTO TMK SLF LNC RGA SLFYF SLF
The largest five individual stock positions are Cisco Systems, Baidu Inc., Berkshire Hathaway, Alphabet, and Johnson & Johnson and they account for ~49% of the portfolio.
PSX AZO RDSB RDSA MRC RHHBF HSB RHHVF CSCO GSK CMCSK CTWS TMK HCS AVT BRK.A HEIO GOOGL JNJ BK RYDBF NVS VZ WFCNP TMK MTSI CCV DVN CCZ BAX GOOG VZA SAFRF COP CKX ANAT RYDAF BIDU HSBC DEO AGCO HBCYF WFC CTWSP FP CTWSO SAFRY RDS.B RDS.A UNP CMCSA MA GSK 0005 SAF CCV.CL KHC HSEA RHHBY HSEB UNF
American International Group Inc. (AIG - Free Report) reported second-quarter 2018 operating earnings of $1.05 per share, missing the Zacks Consensus Estimate by 11.8%. Also, in the year-ago quarter, the company’s bottom line came in at $1.53.
TMK AVF TMK AIG AFL 8686 AFSD GNW 8685
Lincoln National Corporation’s (LNC - Free Report) second-quarter 2018 earnings of $2.02 per share missed the Zacks Consensus Estimate by 3.8%. However, the bottom line improved about 9.2% year over year, mainly led by solid performances across all segments, annuity sales and the recent acquisition of Liberty.
TMK LNC AFL 8686 ENR AFSD GNW TMK
Unum Group’s (UNM - Free Report) second-quarter 2018 operating net income of $1.30 per share beat the Zacks Consensus Estimate by 2.4%. Moreover, the bottom line improved 20.3% year over year on higher premiums and a stable benefits experience. Moreover, lower tax rate provided an additional boost to the metric.
UNM EIG BRK.A TMK AFL 8686 AFSD TMK
Torchmark Corporation’s (TMK - Free Report) second-quarter 2018 net operating income of $1.51 per share beat the Zacks Consensus Estimate by 1.3%. The bottom line also improved nearly 26.9% year over year on the back of higher premiums from the Life and Health segments. Lower share count on continuous buybacks also drove the upside.
TMK PGR MTG TMK RLI
We expect Torchmark Corporation (TMK - Free Report) to surpass expectations in second-quarter 2018 results after the market closes on Jul 25. Last reported quarter, the company delivered a positive earnings surprise of 2.05%. Why a Likely Positive Surprise? Our proven model clearly shows that Torchmark has the right combination of the following two key ingredients to beat estimates this earnings season.
PRU TMK AFW PFK AFGE XL AFA AFGH TMK PRU AFG PRH XLGLF PJH
Aflac Inc. (AFL - Free Report) is scheduled to announce second-quarter 2018 results on Jul 26, after the closing bell. Its quarterly revenues and earnings are expected to improve year over year.
TMK AFW AFGE AFA AFGH TMK AFG AFL AMSF 8686 AFSD
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to LSE:TMK / TORCHMARK CORP on message board site Silicon Investor.
|Trimark Oil and Gas(V.Tmk)||Trimark Oil and Gas(V.Tmk)||Trimark Oil and Gas(V.Tmk)|